Figure 1

Conversion rate to later-line sequential therapy and therapeutic agents. The yellow, red, blue, orange, green, and gray blocks indicate LEN, SORA, atezolizumab plus bevacizumab, SORA, REGO, RAM, and CAB, respectively. Abbreviations: LEN, lenvatinib; SORA, sorafenib; REGO, regorafenib; RAM, ramucirumab; CAB, cabozantinib.